Enveric Biosciences (ENVB) Asset Utilization Ratio (2015 - 2020)
Enveric Biosciences (ENVB) posted Asset Utilization Ratio of 1.28 for Q3 2020, down 3.36% sequentially from 1.32 in Q2 2020, and down 11.92% YoY from 1.45 in Q4 2019.
Enveric Biosciences (ENVB) Asset Utilization Ratio (2015 - 2020) Analysis & Trends
Enveric Biosciences has reported Asset Utilization Ratio for 6 years, with the latest figure at 1.28 in Q3 2020.
- Quarterly Asset Utilization Ratio fell 11.92% year-over-year to 1.28 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 1.28 (down 11.92% YoY) and the FY2019 annual result came in at 2.68, up 155.38% from the prior year.
- Asset Utilization Ratio fell to 1.28 in Q3 2020 per ENVB's latest filing, from 1.32 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 2.85 in Q1 2020 and troughed at 0.93 in Q1 2017.
- A 5-year average of 1.38 and a median of 1.18 in 2016 frame the typical range for Asset Utilization Ratio.
- The sharpest annual moves came in 2017 and 2019: Asset Utilization Ratio tumbled 47.65% in 2017, then surged 134.5% in 2019.
- Over 5 years, Asset Utilization Ratio stood at 0.93 in 2016, then grew by 5.07% to 0.98 in 2017, then advanced by 16.36% to 1.14 in 2018, then soared by 134.5% to 2.67 in 2019, then tumbled by 52.21% to 1.28 in 2020.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 1.28, 1.32, and 2.85 for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 1.28 |
| Jun 30, 2020 | 1.32 |
| Mar 31, 2020 | 2.85 |
| Dec 31, 2019 | 2.67 |
| Sep 30, 2019 | 1.45 |
| Jun 30, 2019 | 1.48 |
| Mar 31, 2019 | 1.42 |
| Dec 31, 2018 | 1.14 |
| Sep 30, 2018 | 0.97 |
| Jun 30, 2018 | 0.99 |
| Mar 31, 2018 | 0.95 |
| Dec 31, 2017 | 0.98 |
| Sep 30, 2017 | 1.05 |
| Jun 30, 2017 | 0.97 |
| Mar 31, 2017 | 0.93 |
| Dec 31, 2016 | 0.93 |
| Sep 30, 2016 | 1.18 |
| Jun 30, 2016 | 1.85 |
| Mar 31, 2016 | 1.74 |
| Dec 31, 2015 | 1.16 |